RALEIGH, NC--(Marketwired - Mar 17, 2014) - Islet Sciences, Inc. (OTCQB: ISLT) today announced that on Monday, March 17, 2014, the Company will host a conference call to discuss the announced acquisition of BHV Pharma. The call is scheduled to take place at 4:15 p.m. ET.
On the call, James Green, Chief Executive Officer, and William Wilkison, Ph.D., Chief Operating Officer, will provide a Company update as well as an overview of the acquisition. The dial-in numbers are 1-877-407-4018 for domestic callers and 1-201-689-8471 for international callers. The conference ID number for both is 13578587. A live webcast of the conference call will also be available on the Investors page of the Company's corporate website at www.isletsciences.com.
After the live webcast, the event will remain archived on the Company's website for one year. In addition, a telephonic replay of the call will be available until March 24, 2014. The replay dial-in numbers are 1-877-870-5176 for domestic callers and 1-858-384-5517 for international callers. Please use event passcode 13578587.
About Islet Sciences, Inc.
Islet Sciences, Inc. is a biopharmaceutical company based in Raleigh, NC, is developing new medicines and technologies for the diagnosis and treatment of metabolic disease. The Company is developing an encapsulated islet cell transplantation therapy for the treatment of type 1 or insulin-dependent diabetes; first-in-class immune-modulating small molecule IL-12 inhibitors that protect insulin-producing beta-cells from cytokines responsible for cell destruction; and a PCR based molecular diagnostic measuring hypomethylated beta cell-derived DNA as a biomarker of beta cell loss for the diagnosis of type 1 diabetes or onset of insulin dependent type 2 diabetes. For more information, please visit www.isletsciences.com.
This press release contains forward-looking statements. Forward-looking statements for Islet Sciences, Inc. reflect current expectations, as of the date of this press release, and involve certain risks and uncertainties. Actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the risks described in the Islet Science, Inc.'s reports filed with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which are outside the Company's control.